Dashboard
Manage Tickers

KNSA Kiniksa Pharmaceuticals Int...

Nasdaq kiniksa.com


$ 38.63 $ -0.28 (-0.72 %)    

Friday, 17-Oct-2025 15:59:58 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 38.64
$ 38.90
$ 37.21 x 50
$ 40.00 x 12
$ 37.85 - $ 39.14
$ 17.82 - $ 39.43
361,365
na
5.73B
$ 0.42
$ 1,176.71
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 07-29-2025 06-30-2025 10-Q
2 04-29-2025 03-31-2025 10-Q
3 02-25-2025 12-31-2024 10-K
4 10-29-2024 09-30-2024 10-Q
5 07-25-2024 06-30-2024 10-Q
6 04-25-2024 03-31-2024 10-Q
7 02-28-2024 12-31-2023 10-K
8 11-02-2023 09-30-2023 10-Q
9 08-01-2023 06-30-2023 10-Q
10 05-04-2023 03-31-2023 10-Q
11 03-02-2023 12-31-2022 10-K
12 11-03-2022 09-30-2022 10-Q
13 08-04-2022 06-30-2022 10-Q
14 05-05-2022 03-31-2022 10-Q
15 02-24-2022 12-31-2021 10-K
16 11-04-2021 09-30-2021 10-Q
17 08-05-2021 06-30-2021 10-Q
18 05-06-2021 03-31-2021 10-Q
19 02-25-2021 12-31-2020 10-K
20 11-05-2020 09-30-2020 10-Q
21 08-04-2020 06-30-2020 10-Q
22 05-04-2020 03-31-2020 10-Q
23 03-05-2020 12-31-2019 10-K
24 11-05-2019 09-30-2019 10-Q
25 08-13-2019 06-30-2019 10-Q
26 05-07-2019 03-31-2019 10-Q
27 03-12-2019 12-31-2018 10-K
28 11-06-2018 09-30-2018 10-Q
29 08-06-2018 06-30-2018 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

5-analysts-have-this-to-say-about-kiniksa-pharmaceuticals
5 Analysts Have This To Say About Kiniksa ...
10/17/2025 19:00:49

citigroup-maintains-buy-on-kiniksa-pharmaceuticals-raises-price-target-to-50
Citigroup Maintains Buy on Kiniksa Pharmac...
10/17/2025 15:23:07

Citigroup analyst Geoff Meacham maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from ...

kiniksa-pharmaceuticals-announces-fda-grants-orphan-drug-designation-for-kpl-387-for-pericarditis
Kiniksa Pharmaceuticals Announces FDA Gran...
10/17/2025 12:06:38

wedbush-maintains-outperform-on-kiniksa-pharmaceuticals-raises-price-target-to-44
Wedbush Maintains Outperform on Kiniksa Ph...
10/13/2025 13:03:03

Wedbush analyst David Nierengarten maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Outperform and raises the price ta...

what-analysts-are-saying-about-kiniksa-pharmaceuticals-stock
What Analysts Are Saying About Kiniksa Pha...
09/29/2025 18:01:32

4 analysts have expressed a variety of opinions on Kiniksa Pharmaceuticals (NASDAQ: KNSA) over the past quarter, offering a div...

td-cowen-initiates-coverage-on-kiniksa-pharmaceuticals-with-buy-rating-announces-price-target-of-60
TD Cowen Initiates Coverage On Kiniksa Pha...
09/29/2025 14:19:16

TD Cowen analyst Nicholas Lorusso initiates coverage on Kiniksa Pharmaceuticals (NASDAQ: KNSA) with a Buy rating and announc...

wells-fargo-maintains-overweight-on-kiniksa-pharmaceuticals-raises-price-target-to-45
Wells Fargo Maintains Overweight on Kiniks...
09/25/2025 13:36:22

Wells Fargo analyst Eva Fortea Verdejo maintains Kiniksa Pharmaceuticals (NASDAQ: KNSA) with a Overweight and raises the pri...

why-commscope-shares-are-trading-higher-by-around-40-here-are-20-stocks-moving-premarket
Why CommScope Shares Are Trading Higher By...
08/04/2025 10:55:34

jefferies-maintains-buy-on-kiniksa-pharmaceuticals-raises-price-target-to-54
Jefferies Maintains Buy on Kiniksa Pharmac...
07/29/2025 21:37:39

Jefferies analyst Roger Song maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $45...

kiniksa-pharmaceuticals-arcalyst-2025-expected-net-product-revenue-guidance-increased-to-625m-640m-compared-to-prior-guidance-of-590m-605m
Kiniksa Pharmaceuticals' ARCALYST 2025 Exp...
07/29/2025 11:34:09

kiniksa-pharmaceuticals-q2-2025-eps-023-beats-018-estimate-sales-156797m-beat-145218m-estimate
Kiniksa Pharmaceuticals Q2 2025 EPS $0.23 ...
07/29/2025 11:32:43

Core News & Articles
Earnings Scheduled For July 29, 2025
07/29/2025 08:32:31

earnings-preview-kiniksa-pharmaceuticals
Earnings Preview: Kiniksa Pharmaceuticals
07/28/2025 18:01:57

Core News & Articles
12 Health Care Stocks Moving In Friday's A...
07/25/2025 21:06:49

wells-fargo-maintains-overweight-on-kiniksa-pharmaceuticals-raises-price-target-to-42
Wells Fargo Maintains Overweight on Kiniks...
07/09/2025 13:14:44

Wells Fargo analyst Eva Fortea Verdejo maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Overweight and raises the pric...

kiniksa-pharma-announces-details-for-planned-phase-23-clinical-trial-of-kpl-387-in-recurrent-pericarditis-expected-to-initiate-in-middle-of-2025
Kiniksa Pharma Announces Details For Plann...
06/05/2025 11:07:35

– KPL-387 Phase 2/3 trial on track to initiate in mid-2025; Phase 2 data expected in 2H 2026 –– KPL-387 Phase 1 single ascendin...

Core News & Articles
10 Health Care Stocks Whale Activity In To...
05/05/2025 17:35:21

pony-ai-hims--hers-and-frontdoor-are-among-top-11-mid-cap-gainers-last-week-apr-28-may-2-are-the-others-in-your-portfolio
Pony AI, Hims & Hers And Frontdoor Are Amo...
05/04/2025 15:46:29

Top performers last week: PONY, HIMS, ODD, MTSR, CGON, KNSA, KC, FTDR, ATI, PRDO, and IRTC. Have you invested in them?

honeywell-posts-better-than-expected-q1-earnings-joins-crown-holdings-noble-crane-and-other-big-stocks-moving-higher-on-tuesday
Honeywell Posts Better-Than-Expected Q1 Ea...
04/29/2025 14:36:32

kiniksa-pharmaceuticals-raises-fy2025-sales-guidance-from-56000m-58000m-to-59000m-60500m-vs-69899m-est
Kiniksa Pharmaceuticals Raises FY2025 Sale...
04/29/2025 11:33:41

Kiniksa Pharmaceuticals (NASDAQ:KNSA) raises FY2025 sales outlook from $560.00 million-$580.00 million to $590.00 million-$605....

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION